AUTHORS
Rami Komrokji, MD, Rumana Tokaria, MD2, Najla Al Ali, MS3, Zhuoer Xie, MD,MS4, Rory Shallis, MD5, Onyee Chan, MD6, Andrew T Kuykendall, MD7, Samuel Benjamin Reynolds, MD8, Seongseok Yun, MD, PhD9, Joseph Jabbour10, Kendra L. Sweet, MD, MS11, Alison Walker, MD12, Jeffrey Lancet, MD13, Eric Padron, MD14, David Sallman, MD15
AFFILIATIONS
1 Moffitt Cancer Center, Tampa, Florida, United States
2 Moffitt Cancer Center, Tampa, Florida, United States
3 Moffitt Cancer Center, Tampa, Florida, United States
4 Moffitt Cancer Center, Tampa, Florida, United States
5 Moffitt Cancer Center, Tampa, Florida, United States
6 Moffitt Cancer Center, Tampa, Florida, United States
7 Moffitt Cancer Center, Tampa, Florida, United States
8 Moffitt Cancer Center, Tampa, Florida, United States
9 Moffitt Cancer Center, Tampa, Florida, United States
10 Moffitt Cancer Center, Tampa, Florida, United States
11 Moffitt Cancer Center, Tampa, Florida, United States
12 Moffitt Cancer Center, Tampa, Florida, United States
13 Moffitt Cancer Center, Tampa, Florida, United States
14 Moffitt Cancer Center, Tampa, Florida, United States
15 Moffitt Cancer Center, Tampa, Florida, United States
ABSTRACT
Background:
TP53 mutations (MT) are associated with worst outcome in myelodysplastic syndromes (MDS). This is particularly correlated with bi-allelic/multi hit status of TP53 MT defined as two different hot spot MT in trans, variant allele frequency >50%, deletion/cnLOH of chromosome 17. Majority of TP53 MT are classified as missense at DNA binding site, outside DNA binding site, contact, and conformational. Less commonly tuncating MT are encountered (non-sense, inframe, or splicing). TP53 mutational status had been extensively examined in context of allelic status, blasts% and complex karyotype but little is known about the relevance of the type of mutation.
Methods:
We interrogated our fully annotated Moffitt MDS database for TP53 MT MDS cases with known hotspot mutation. We categorized mutations into 2 main groups: missense and truncating mutations. We compared baseline characteristics, response to treatment and outcomes accordingly. Biallelic/multi hit status was categorized accoring to ICC 2022 criteria.
Results:
We identified 748 TP53 MT MDS cases. They were grouped based on predicted hot spot : missense DNA-binding domain 54.8% (410), missense outside DNA-binding domain 5.6% (42), missense DNA-contact 12.2% (91), missense conformational 9.4% (70), and truncating (non-sense, inframe, or splicing) 15% (112). Unclassified MT were 3.1% (23). We compared missense (n=613) to truncating (n=112) MT.
Baseline characteristics including age, gender, Hgb, WBC, blasts, complex karyotype, and IPSS-M were similar. Truncating MT group had lower platelets count (median 58 vs 78, p=0.009) and were more likely to be biallelic/multi hit (65.3% vs 49%, p=.0004). There was also a non-significant tendency of being classified as therapy-related MDS in the truncating group, (45.5% versus 36.4%, p = 0.08).
Among 594 pts treated with hypomethylating agents (HMA) alone or in combination with venetoclax or investigational agents, there was no difference in response rate. The odds ratio of Overall response (ORR) (CR, PR, mCR and HI) was 0.82, 95% CI 0.51-1.32, p= 0.42.
The median Overall survival (OS) was 12 months for tuncating MT group compared to 14 months for missense MT group. (HR 1.27, 95% CI-1.02-1.59, p=0.03). After adjusting for both multi-hit/biallelic TP53 status and IPSS-M, truncating MT were no longer independently associated with worse OS. The adjusted HR for truncating MT compared to missense MT was 1.11, 95% CI 0.87-1.4, p = 0.41. Multi-hit/biallelic TP53 status-HR 1.22, 95% CI 1.02–1.46, p = 0.026 and IPSS-M-HR 1.39, 95% CI 1.30–1.47, p <0.001
For patients who underwent allogeneic hematopoietic stem cell transplant (AHSCT) (n=128), median post-AHSCT OS was 8.5 months for truncating MT versus 22.8 months for missense MT. The post-AHSCT mortality HR was 1.82, 95% CI 1.13–2.92, p = 0.012. Two-year post-AHSCT OS was 18.5% in the truncating MT group versus 49.0% in missense group. Truncating MT had adjusted HR 1.92 for death after AHSCT 95% CI 1.08–3.41, p = 0.026 accounting for bi-allelic/multihit status, IPSS-M, type and intensity of AHSCT. In the AHSCT subset, neither multi-hit/biallelic status nor IPSS-M reached significance: multi-hit/biallelic status HR 0.99, p = 0.97 and IPSS-M HR 1.12, p = 0.24. Donor type and conditioning intensity were not independent predictors of OS. There was no difference in response to HMA treatment prior to transplant. Among 52 biallelic/multi hit group who proceeded to AHSCT, 34 were misense and 18 truncating MT. A clinically meaningful trend in OS was observed but not significant given sample size. The median OS was 22.8 mo vs 7.8 mo, respectively (truncating MT HR 1.61 95% CI 0.83-3.12) (p=0.15)
Conclusions
TruncatingTP53 mutations (non-sense, inframe, or splicing) were observed in 15% of MDS cases. They are associated with more likelihood of bi-allelic/multi hit status, thrombocytopenia and tendency to occur more in therapy related MDS. The worse overall survival of truncating MT compared to missense was driven by bi-allelic/multi hit status. Interestingly, we observed worse OS among truncating MT group who underwent AHSCT independent of allelic status which warrants further investigation.
DISCLOSURES
Rami Komrokji, MD: Abbvie - Honoraria; syndax - Honoraria; Takeda - Honoraria; Stemline - Honoraria; DSI - Honoraria; BMS - Honoraria; GSK - Honoraria; RIGEL - Honoraria; Sobi - Honoraria; Kura - Honoraria; Servier - Honoraria; Novartis - Honoraria; Sumitomo - Honoraria; GERON - Honoraria; PharmaEssentia - Honoraria; BMS - Research Funding; Takeda - Consultancy (Includes expert testimony); RIGEL - Consultancy (Includes expert testimony); syndax - Consultancy (Includes expert testimony); Sobi - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); PharmaEssentia - Consultancy (Includes expert testimony); Servier - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Abbvie - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); DSI - Consultancy (Includes expert testimony); GERON - Consultancy (Includes expert testimony); Kura - Consultancy (Includes expert testimony); Stemline - Consultancy (Includes expert testimony); Sumitomo - Consultancy (Includes expert testimony)